A5083580986- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Cerebral Venous Sinus Thrombosis
- Health Systems, Economic Evaluations, Quality of Life
- Rheumatoid Arthritis Research and Therapies
- Retinal and Optic Conditions
- Nerve injury and regeneration
- Mast cells and histamine
- Reproductive System and Pregnancy
- Powdery Mildew Fungal Diseases
- Eosinophilic Disorders and Syndromes
- Acute Lymphoblastic Leukemia research
- Long-Term Effects of COVID-19
- Systemic Sclerosis and Related Diseases
- Family Support in Illness
- BRCA gene mutations in cancer
- Psychosomatic Disorders and Their Treatments
- Pathogenesis and Treatment of Hiccups
- Clinical Reasoning and Diagnostic Skills
- RNA regulation and disease
- Patient-Provider Communication in Healthcare
- Neurogenesis and neuroplasticity mechanisms
- Drug-Induced Adverse Reactions
- Autoimmune and Inflammatory Disorders Research
Hospital Rafael Méndez
2016-2024
University of Perugia
2005-2008
Istituti di Ricovero e Cura a Carattere Scientifico
2007
Fondazione Santa Lucia
2007
Sixty, relapsing remitting (RR) multiple sclerosis (MS) patients, who underwent treatment with glatiramer acetate (GA), interferon (IFN)-β 1a, and immunoglobulins (Igs) (20 per group), were assessed for levels of brain-derived neurotrophic factor (BDNF) in the supernatants unstimulated stimulated peripheral blood mononuclear cells (PBMCs) first year treatment. Phytohemagglutinin (PHA), anti-OKT3 antibody, myelin basic protein (MPB) GA used as stimuli. Cytokine responses by ELISPOT...
Abstract Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness treatment for a real‐world setting. Methods We conducted retrospective including consecutive from nine public hospitals south‐eastern Spain who received after it approved. Results A total 228 MS were included (144...
Fatigue in multiple sclerosis is a key symptom associated with work-related problems and poor quality of life outcomes. The five-item Modified Impact Scale brief self-assessment tool for measuring the impact fatigue on cognitive, physical psychosocial function. A non-interventional, cross-sectional study was conducted to assess dimensionality item characteristics sclerosis. total 302 subjects were studied. Mokken analysis found strong one-dimensional scale (overall scalability index H =...
The aim of the present study was to verify cerebrospinal fluid (CSF) levels glial cell line-derived neurotrophic factor (GDNF) and somatostatin, both measured by sensitive immunoassay, in: 16 chronic migraine (CM) patients, 15 patients with an antecedent history without aura diagnosed as having probable (PCM) analgesic-abuse headache (PAAH), 20 affected primary fibromyalgia syndrome (PFMS), control subjects. Significantly lower GDNF somatostatin were found in CSF CM PCM + PAAH compared...
Background and purpose: In recent years, different approaches have been used to investigate changes of cerebrospinal fluid (CSF) proteome in patients affected by multiple sclerosis (MS) with the aim identify protein markers potential diagnostic or prognostic value. Because lack standardization current proteomic techniques, contrasting results were achieved until now laboratories. this study, we compare CSF 10 relapsing–remitting MS (RR‐MS) patients, 11 clinically isolated syndrome (CIS),...
Objective we aimed to evaluate the utility of transorbital ultrasonography (TOS) in optic nerve assessment and quantification ON atrophy MS patients, determine whether correlates with disease duration disability measured on Kurtzke Expanded Disability Status Scale (EDSS). Materials methods Prospective, multicentre, blinded cohort study 59 patients diagnosed relapsing-remitting 36 controls. Results When TOS, diameter both right (2.69 ± 0.30 mm cases; 3.20 0.19 controls, P < .0001) left (2.71...
<b><i>Objective:</i></b> To determine the effect of disease-modifying drugs (DMDs) on disease activity rebound in patients discontinuing natalizumab (NTZ). <b><i>Methods:</i></b> Twenty-one with relapsing-remitting multiple sclerosis (RRMS) treated NTZ for ≥1 year and who switched to DMDs (glatiramer acetate [GA] or interferon) were followed up 12 months clinical practice. Clinical outcomes after cessation assessed every 3 1 MRI was performed...
Status quo (SQ) bias is defined as patient´s tendency to continue taking a previously selected but inferior therapeutic option.To assess the presence of SQ and its associated factors in patients with relapsing-remitting multiple sclerosis (RRMS).A multicenter, non-interventional study involving 211 RRMS was conducted. Participants answered questions regarding risk preferences management simulated MS case-scenarios. The SymptoMScreen (SMSS) questionnaire used perception severity from...
The aim of this study was to assess the phenomenon patients' decisional conflict regarding choice a disease-modifying therapy.
The aim of this study was to assess relapsing-remitting multiple sclerosis (RRMS) patients' preferred role in making treatment decisions.
A multicenter study involving 204 adults with relapsing-remitting multiple sclerosis (RRMS) assessed the dimensionality and item characteristics of Mishel-Uncertainty Illness Scale (MUIS), a generic self-assessment tool. Mokken analysis identified two dimensions in MUIS an appropriate overall scale scalability after excluding nonclassifiable items. refined 12-item MUIS, employing grade response model, effectively discriminated uncertainty levels among RRMS patients (likelihood ratio test
Depression is one of the most prevalent psychiatric conditions in adulthood, reaching figures around 20%. The methodologies used to study depression are varied, and range from a self-administered test structured assessment. Several studies patients with multiple sclerosis (MS) have been conducted last 20 years, 35% found for depressive symptoms, while disorders less frequent, at approximately 21%.
Purpose: Shared decision-making is critical in multiple sclerosis (MS) due to the uncertainty of disease trajectory over time and large number treatment options with differing efficacy, safety administration characteristics. The aim this study was assess patients' decisional conflict regarding choice a disease-modifying therapy its associated factors patients mid-stage relapsing-remitting (RRMS). Methods: A multicenter, non-interventional conducted. Adult diagnosis RRMS (2017 revised...
Wells syndrome, also known as eosinophilic cellulitis, is a rare dermatosis with approximately 200 cases previously described in the literature. Here, we present case of patient multiple sclerosis syndrome induced by dimethyl fumarate (DMF).